-
1
-
-
84890077367
-
Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China
-
Wang J, Chen RP, Lei L, et al. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. Asia Pac J Clin Nutr. 2013;22:590–598.
-
(2013)
Asia Pac J Clin Nutr
, vol.22
, pp. 590-598
-
-
Wang, J.1
Chen, R.P.2
Lei, L.3
-
2
-
-
85008612450
-
Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review
-
Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8:537–548.
-
(2017)
J Adv Res
, vol.8
, pp. 537-548
-
-
Sharaf El Din, U.A.A.1
Salem, M.M.2
Abdulazim, D.O.3
-
3
-
-
85015266193
-
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
-
Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19:897–900.
-
(2017)
Diabetes Obes Metab
, vol.19
, pp. 897-900
-
-
Desai, M.1
Yavin, Y.2
Balis, D.3
-
4
-
-
58149357463
-
Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
-
Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11:79–88.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 79-88
-
-
Idris, I.1
Donnelly, R.2
-
5
-
-
85021986989
-
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
-
Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;1–5.
-
(2017)
Diabetes Obes Metab
, pp. 1-5
-
-
Chilton, R.1
Tikkanen, I.2
Hehnke, U.3
Woerle, H.J.4
Johansen, O.E.5
-
6
-
-
84969784577
-
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
-
Leiter LA, Cefalu WT, de Bruin TW, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18:766–774.
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 766-774
-
-
Leiter, L.A.1
Cefalu, W.T.2
de Bruin, T.W.3
-
7
-
-
84969915634
-
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
-
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 783-794
-
-
Zaccardi, F.1
Webb, D.R.2
Htike, Z.Z.3
Youssef, D.4
Khunti, K.5
Davies, M.J.6
-
8
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
9
-
-
85021244090
-
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
-
Xu L-B, Li Y, Lang J-X, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ. 2017;5:e3405.
-
(2017)
PeerJ
, vol.5
-
-
Xu, L.-B.1
Li, Y.2
Lang, J.-X.3
-
10
-
-
84924677348
-
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
-
Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–429.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 426-429
-
-
Davies, M.J.1
Trujillo, A.2
Vijapurkar, U.3
Damaraju, C.V.4
Meininger, G.5
-
11
-
-
85047692188
-
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
-
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
-
(1995)
JAMA
, vol.273
, pp. 408-412
-
-
Schulz, K.F.1
Chalmers, I.2
Hayes, R.J.3
Altman, D.G.4
-
12
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
-
(2002)
Stat Med
, vol.21
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
13
-
-
84895484977
-
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
-
Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204–221.
-
(2014)
Diabetes Metab Res Rev
, vol.30
, pp. 204-221
-
-
Zhang, M.1
Zhang, L.2
Wu, B.3
Song, H.4
An, Z.5
Li, S.6
-
14
-
-
84860183617
-
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials
-
Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
-
(2012)
Ann Med
, vol.44
, pp. 375-393
-
-
Musso, G.1
Gambino, R.2
Cassader, M.3
Pagano, G.4
-
15
-
-
84938924986
-
Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis
-
Fan Y, Wei F, Lang Y, Wang S. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens. 2015;33:681–688.
-
(2015)
J Hypertens
, vol.33
, pp. 681-688
-
-
Fan, Y.1
Wei, F.2
Lang, Y.3
Wang, S.4
-
16
-
-
84975707191
-
Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis
-
Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76:947–956.
-
(2016)
Drugs
, vol.76
, pp. 947-956
-
-
Derosa, G.1
Maffioli, P.2
Reiner, Z.3
Simental-Mendia, L.E.4
Sahebkar, A.5
-
17
-
-
84942872229
-
Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials
-
Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
-
(2015)
Pharmacol Res
, vol.102
, pp. 63-70
-
-
Derosa, G.1
Maffioli, P.2
Sahebkar, A.3
-
18
-
-
5344244028
-
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
-
Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148:635–640.
-
(2004)
Am Heart J
, vol.148
, pp. 635-640
-
-
Milionis, H.J.1
Kakafika, A.I.2
Tsouli, S.G.3
-
19
-
-
84885056806
-
Hypouricaemia and hyperuricosuria in familial renal glucosuria
-
Aires I, Santos AR, Pratas J, Nolasco F, Calado J. Hypouricaemia and hyperuricosuria in familial renal glucosuria. Clin Kidney J. 2013;6:523–525.
-
(2013)
Clin Kidney J
, vol.6
, pp. 523-525
-
-
Aires, I.1
Santos, A.R.2
Pratas, J.3
Nolasco, F.4
Calado, J.5
-
20
-
-
84920971105
-
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
-
Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308:F77–F83.
-
(2015)
Am J Physiol Renal Physiol
, vol.308
, pp. F77-F83
-
-
Lytvyn, Y.1
Skrtic, M.2
Yang, G.K.3
Yip, P.M.4
Perkins, B.A.5
Cherney, D.Z.6
-
21
-
-
84908555003
-
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
-
Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.
-
(2014)
Biopharm Drug Dispos
, vol.35
, pp. 391-404
-
-
Chino, Y.1
Samukawa, Y.2
Sakai, S.3
|